Experts Predict USVM Will Hit $100
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Aug 22 2025
0mins
Source: NASDAQ.COM
ETF Analysis: The VictoryShares US Small Mid Cap Value Momentum ETF (USVM) has an implied analyst target price of $99.58 per unit, indicating a potential upside of 15.50% from its current trading price of $86.22.
Notable Holdings: Key underlying holdings with significant upside include Spectrum Brands Holdings Inc (SPB), Clover Health Investments Corp (CLOV), and Alignment Healthcare Inc (ALHC), each showing potential increases based on average analyst target prices.
Analyst Target Comparisons: SPB's recent price is $54.47 with a target of $80.50 (47.79% upside), CLOV is at $2.61 with a target of $3.65 (39.85% upside), and ALHC is priced at $15.80 with a target of $18.90 (19.62% upside).
Investor Considerations: Questions arise regarding the validity of these analyst targets, whether they are justified or overly optimistic, highlighting the need for further investor research into company and industry developments.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy CLOV?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on CLOV
Wall Street analysts forecast CLOV stock price to fall
2 Analyst Rating
1 Buy
1 Hold
0 Sell
Moderate Buy
Current: 5.390
Low
3.00
Averages
3.35
High
3.70
Current: 5.390
Low
3.00
Averages
3.35
High
3.70
About CLOV
Clover Health Investments, Corp. is a physician enablement technology company. The Company is focused on bringing access to healthcare to everyone on Medicare. This includes a focus on seniors, who have historically lacked access to affordable healthcare. Its software platform, Clover Assistant, is a technology platform that empowers providers to deliver intuitive data-driven, personalized care to help physicians detect, identify, and manage diseases earlier. This physician-enablement platform is designed to synthesize comprehensive, longitudinal sets of data to generate provider-focused machine learning, artificial intelligence and rules-based insights, and to drive action by surfacing the relevant, personalized information about each patient to his or her provider. The Company, through its Insurance segment, provides Preferred Provider Organization (PPO) and Health Maintenance Organization (HMO) plans to Medicare Advantage (MA) members in several states.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Clover Health Board Member Sells 67,160 Shares
- Transaction Overview: On May 18, 2026, Dr. Carladenise Armbrister Edwards, a member of Clover Health's Board of Directors, reported a direct sale of 67,160 shares, valued at approximately $230,000, indicating a reduction in her stake in the company.
- Holding Changes: This transaction reduced Edwards' direct holdings by 19.05%, from 352,592 shares to 285,432 shares, reflecting a decrease in available holdings that may stem from routine portfolio management practices.
- Market Performance Impact: The sale price of around $3.42 per share was slightly below the market close, occurring during a period when the stock's one-year total return was 8.23%, suggesting that muted market performance may have influenced her decision to sell.
- Company Performance Highlights: Clover Health reported a 62% year-over-year revenue increase in Q1 2026, reaching $749.2 million, with a 51% rise in Medicare Advantage memberships, transitioning from a net loss of $1.3 million in Q1 2025 to a net income of $27.3 million this year, showcasing strong performance in the healthcare insurance market.
See More
Clover Health Director Sells Shares Amid Price Surge
- Share Sale Details: Director Carladenise Edwards sold 67,160 shares on May 18, 2026, at a weighted average price of approximately $3.42 per share, totaling around $230,000, which represented 19% of her direct holdings, reducing her ownership from 352,592 to 285,432 shares.
- Market Reaction Analysis: This sale occurred during a period of rising stock prices following Clover Health's excellent first-quarter earnings report, with shares reaching a 52-week high of $5.49 on June 26, indicating strong market confidence in the company's future growth prospects.
- Financial Performance Highlights: Clover Health reported a 62% year-over-year revenue increase in Q1 2026, reaching $749.2 million, with Medicare Advantage memberships growing by 51%, successfully turning around from a net loss of $1.3 million in Q1 2025 to a net income of $27.3 million, showcasing robust business recovery.
- Investor Advisory: Despite Clover Health's impressive performance, the Motley Fool analyst team did not include it in their current list of top investment stocks, advising investors to exercise caution and consider overall market performance and potential risks when making investment decisions.
See More
Jim Cramer's Insights on Multiple Stocks
- Fair Isaac Concerns: Despite growing worries about Fair Isaac's exposure to AI, analysts maintain a positive long-term outlook but choose to stay on the sidelines due to market uncertainties, reflecting caution regarding AI's impact on traditional business models.
- Clover Health Investment Strategy: Analysts acknowledge their overly conservative view on Clover Health, recognizing its speculative potential while favoring long-term holdings in United Health and CVS, indicating a preference for more stable companies.
- Vistra Price Volatility: Vistra's stock has experienced significant fluctuations, with analysts suggesting that the current price is too low and recommending a gradual build-up of positions, highlighting sensitivity to short-term market movements and expectations of a rebound.
- Stryker Consolidation Expectations: Analysts express disappointment that Stryker's anticipated consolidation has not materialized, indicating a failure of the market to deliver expected consolidation opportunities and reflecting a sense of disillusionment with industry consolidation trends.
See More
Biotech Companies See Significant Stock Gains
- Parabilis Debut Performance: Parabilis Medicines Inc. saw its stock surge 58% on its Nasdaq debut, pricing 33.5 million shares at $20 each, with expected gross proceeds of approximately $670 million, indicating strong market demand for its innovative drug candidates.
- Clover Health Legal Victory: Clover Health Investments Corp. achieved a legal victory against the U.S. Department of Health and Human Services, upgrading its PPO plan's star rating from 3.5 to 4.5, with projected total revenues for 2026 between $2.81 billion and $2.92 billion, reflecting a 49% year-over-year growth.
- Shoulder Innovations Growth: Shoulder Innovations, Inc. reported a net revenue of $16.7 million for Q1, a 65% increase year-over-year, and expects full-year 2026 revenues between $65 million and $68 million, representing a growth of 37% to 44%, showcasing its strong position in the shoulder surgical market.
- Myomo Stock Surge: Myomo Inc.'s stock rose over 17%, with projected Q2 2026 revenues between $10.3 million and $10.8 million, compared to $9.7 million in Q2 2025, reflecting increasing market demand for its wearable medical robotics products.
See More
Clover Health Plan Rating Upgrade Boosts Stock
- Rating Upgrade Impact: The U.S. District Court for the Southern District of Georgia ordered CMS to recalculate Clover's 2026 Star Rating, raising it from 3.5 to 4.5 stars, which will affect payment rates for 2027 and is expected to lead to higher bonus payments, thereby boosting revenue.
- Stock Price Surge: Shares of Clover Health Investments (CLOV) surged over 17% following the ruling, reaching their highest levels since November 2021, reflecting investor optimism about future revenue growth, especially given the company's claim of losing approximately $120 million in bonuses due to the rating reduction.
- Market Sentiment Shift: Retail sentiment surrounding CLOV on Stocktwits shifted from neutral to 'extremely bullish' amid high message volume, with investors widely believing that the ruling's impact could extend beyond the anticipated $120 million in revenue, with some predicting the stock could reach as high as $60 by 2027.
- Legal Context: Clover filed a lawsuit last November, claiming that CMS improperly implemented 20 quality measures that led to the downgrade of its PPO plan's Star Rating, and the court's ruling provides legal backing and market confidence for Clover's future growth.
See More
Clover Health and Chewy Show High Options Trading Volume
- Clover Health Options Volume: Clover Health Investments Corp (CLOV) has seen an options trading volume of 57,304 contracts today, representing approximately 5.7 million shares, which is 70.2% of its average daily trading volume of 8.2 million shares over the past month.
- High Call Option Activity: Within CLOV, the $4.50 strike call option has traded 14,324 contracts today, equating to about 1.4 million shares, indicating strong market expectations for the stock's future appreciation.
- Chewy Options Trading Dynamics: Chewy Inc (CHWY) has recorded an options trading volume of 61,142 contracts today, representing approximately 6.1 million shares, or 66.7% of its average daily trading volume of 9.2 million shares over the past month.
- Active Put Option: For CHWY, the $18 strike put option has seen 8,658 contracts traded today, amounting to approximately 865,800 shares, reflecting market concerns about potential declines in the stock's price.
See More
Clover Health Board Member Sells 67,160 Shares
- Transaction Overview: On May 18, 2026, Dr. Carladenise Armbrister Edwards, a member of Clover Health's Board of Directors, reported a direct sale of 67,160 shares, valued at approximately $230,000, indicating a reduction in her stake in the company.
- Holding Changes: This transaction reduced Edwards' direct holdings by 19.05%, from 352,592 shares to 285,432 shares, reflecting a decrease in available holdings that may stem from routine portfolio management practices.
- Market Performance Impact: The sale price of around $3.42 per share was slightly below the market close, occurring during a period when the stock's one-year total return was 8.23%, suggesting that muted market performance may have influenced her decision to sell.
- Company Performance Highlights: Clover Health reported a 62% year-over-year revenue increase in Q1 2026, reaching $749.2 million, with a 51% rise in Medicare Advantage memberships, transitioning from a net loss of $1.3 million in Q1 2025 to a net income of $27.3 million this year, showcasing strong performance in the healthcare insurance market.
See More
Clover Health Director Sells Shares Amid Price Surge
- Share Sale Details: Director Carladenise Edwards sold 67,160 shares on May 18, 2026, at a weighted average price of approximately $3.42 per share, totaling around $230,000, which represented 19% of her direct holdings, reducing her ownership from 352,592 to 285,432 shares.
- Market Reaction Analysis: This sale occurred during a period of rising stock prices following Clover Health's excellent first-quarter earnings report, with shares reaching a 52-week high of $5.49 on June 26, indicating strong market confidence in the company's future growth prospects.
- Financial Performance Highlights: Clover Health reported a 62% year-over-year revenue increase in Q1 2026, reaching $749.2 million, with Medicare Advantage memberships growing by 51%, successfully turning around from a net loss of $1.3 million in Q1 2025 to a net income of $27.3 million, showcasing robust business recovery.
- Investor Advisory: Despite Clover Health's impressive performance, the Motley Fool analyst team did not include it in their current list of top investment stocks, advising investors to exercise caution and consider overall market performance and potential risks when making investment decisions.
See More
Jim Cramer's Insights on Multiple Stocks
- Fair Isaac Concerns: Despite growing worries about Fair Isaac's exposure to AI, analysts maintain a positive long-term outlook but choose to stay on the sidelines due to market uncertainties, reflecting caution regarding AI's impact on traditional business models.
- Clover Health Investment Strategy: Analysts acknowledge their overly conservative view on Clover Health, recognizing its speculative potential while favoring long-term holdings in United Health and CVS, indicating a preference for more stable companies.
- Vistra Price Volatility: Vistra's stock has experienced significant fluctuations, with analysts suggesting that the current price is too low and recommending a gradual build-up of positions, highlighting sensitivity to short-term market movements and expectations of a rebound.
- Stryker Consolidation Expectations: Analysts express disappointment that Stryker's anticipated consolidation has not materialized, indicating a failure of the market to deliver expected consolidation opportunities and reflecting a sense of disillusionment with industry consolidation trends.
See More
Biotech Companies See Significant Stock Gains
- Parabilis Debut Performance: Parabilis Medicines Inc. saw its stock surge 58% on its Nasdaq debut, pricing 33.5 million shares at $20 each, with expected gross proceeds of approximately $670 million, indicating strong market demand for its innovative drug candidates.
- Clover Health Legal Victory: Clover Health Investments Corp. achieved a legal victory against the U.S. Department of Health and Human Services, upgrading its PPO plan's star rating from 3.5 to 4.5, with projected total revenues for 2026 between $2.81 billion and $2.92 billion, reflecting a 49% year-over-year growth.
- Shoulder Innovations Growth: Shoulder Innovations, Inc. reported a net revenue of $16.7 million for Q1, a 65% increase year-over-year, and expects full-year 2026 revenues between $65 million and $68 million, representing a growth of 37% to 44%, showcasing its strong position in the shoulder surgical market.
- Myomo Stock Surge: Myomo Inc.'s stock rose over 17%, with projected Q2 2026 revenues between $10.3 million and $10.8 million, compared to $9.7 million in Q2 2025, reflecting increasing market demand for its wearable medical robotics products.
See More
Clover Health Plan Rating Upgrade Boosts Stock
- Rating Upgrade Impact: The U.S. District Court for the Southern District of Georgia ordered CMS to recalculate Clover's 2026 Star Rating, raising it from 3.5 to 4.5 stars, which will affect payment rates for 2027 and is expected to lead to higher bonus payments, thereby boosting revenue.
- Stock Price Surge: Shares of Clover Health Investments (CLOV) surged over 17% following the ruling, reaching their highest levels since November 2021, reflecting investor optimism about future revenue growth, especially given the company's claim of losing approximately $120 million in bonuses due to the rating reduction.
- Market Sentiment Shift: Retail sentiment surrounding CLOV on Stocktwits shifted from neutral to 'extremely bullish' amid high message volume, with investors widely believing that the ruling's impact could extend beyond the anticipated $120 million in revenue, with some predicting the stock could reach as high as $60 by 2027.
- Legal Context: Clover filed a lawsuit last November, claiming that CMS improperly implemented 20 quality measures that led to the downgrade of its PPO plan's Star Rating, and the court's ruling provides legal backing and market confidence for Clover's future growth.
See More
Clover Health and Chewy Show High Options Trading Volume
- Clover Health Options Volume: Clover Health Investments Corp (CLOV) has seen an options trading volume of 57,304 contracts today, representing approximately 5.7 million shares, which is 70.2% of its average daily trading volume of 8.2 million shares over the past month.
- High Call Option Activity: Within CLOV, the $4.50 strike call option has traded 14,324 contracts today, equating to about 1.4 million shares, indicating strong market expectations for the stock's future appreciation.
- Chewy Options Trading Dynamics: Chewy Inc (CHWY) has recorded an options trading volume of 61,142 contracts today, representing approximately 6.1 million shares, or 66.7% of its average daily trading volume of 9.2 million shares over the past month.
- Active Put Option: For CHWY, the $18 strike put option has seen 8,658 contracts traded today, amounting to approximately 865,800 shares, reflecting market concerns about potential declines in the stock's price.
See More
